Calendario›TCRT›Ad-RTS-hIL-12
Ad-RTS-hIL-12
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Ensayo de Alaunos Therapeutics, Inc. en Glioblastoma.
Más ensayos de: Glioblastoma.
- Fase
- Fase 2
- Estado
- Interrumpido
- Participantes
- 40
- Centros
- 7
- Fin del objetivo primario
- ago 2021
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en ago 2019.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor Decision».
Qué mide
Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Combination With Cemiplimab-rwlc in Subjects With Recurrent or Progressive Glioblastoma. (2.0 yrs) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo (cemiplimab-rwlc) is currently FDA approved in the United States for metastatic cutaneous cell carcinoma (CSCC), but is not approved in glioblastoma. Cemiplimab-rwlc may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with cemiplimab-rwlc to enhance the IL-12 mediated effect observed to date. The main purpose of this study is to evaluate the safety and efficacy of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with cemiplimab-rwlc.
Más ensayos de TCRT
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Neoantigen specific TCR-T cell… | no aplica | Completado | may 2025 (real) |
| HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | no aplica | Interrumpido | ago 2023 (real) |
| Neoantigen specific TCR-T cell… | Fase 1/2 | Interrumpido | ago 2023 (real) |
| Ad-RTS-hIL-12 | Fase 1/2 | Interrumpido | sep 2021 (real) |
| Ad-RTS-hIL-12 | Fase 1 | Completado | oct 2020 (real) |
| Ad-RTS-hIL-12 | Fase 1 | Completado | ago 2019 (real) |
Todos los de TCRT, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04006119), actualizada en mar 2025.